AstraZeneca To Boost Clinical Trial Investment In Japan By Third (Japan)
This article was originally published in PharmAsia News
AstraZeneca says it intends to place more than 20 drug candidates in clinical trials in Japan next fiscal year, backed by a $90 billion investment. CEO David Brennan said the investment would be 30 percent more than the company spent this year on Japan-based research, breaking a go-slow attitude the firm had in the past towards Japan. The drug candidates include ones for cancer and heart disease. This fiscal year, the firm tested fewer than 20 drugs for Japanese approval. (Click here for more - may require paid subscription
You may also be interested in...
Non-profit approach is reassuring for healthcare payers, but vaccines won’t be ready to stop pandemic at its peak.
Executives On The Move: BMS Taps Barclays Exec For Strategy Spot, Epizyme Selects Science Chief And A Board Election At ADC Therapeutics
Bristol-Myers Squibb taps Barclays chair of global life sciences as it EVP, strategy and business development, and cancer therapeutics firm Epizyme Inc. selects a chief scientific officer. At ADC Therapeutics, an oncology drug development company, a new chairman is elected.